LTGO-33

LTGO-33 is a potent and selective voltage-gated sodium channel NaV1.8 inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human DRG neurons, where it reduces action potential firing. LTGO-33 can be used for pain disorders research[1].

Product Specifications

CAS Number

[2834106-06-6]

UNSPSC

12352005

Target

Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ltgo-33.html

Purity

99.35

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC1=CC(C)=C(OC2=NC=C(C=C2C(NC3=CC=CC([S@](=O)(C)=N)=C3)=O)C(F)(F)F)C=C1

Molecular Formula

C21H17F4N3O3S

Molecular Weight

467.44

References & Citations

[1]Gilchrist JM, et al. Pharmacologic Characterization of LTGO-33, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel NaV1.8 with a Unique Mechanism of Action. Mol Pharmacol. 2024 Feb 15;105 (3) :233-249.